Brian S. Posner, Director at Dyne Therapeutics, Inc. (DYN), bought 3,000 shares at $15.06 ($45K) on 2026-03-06, disclosed to the SEC on 2026-03-10.
Director Brian Posner executed the largest purchase of his career, buying 3,000 shares at $15.06 on March 6, 2026, signaling confidence in the stock's trajectory. This move comes as the stock has rallied significantly over the past year, potentially positioning the insider to capitalize on upcoming regulatory milestones.
DYN shares have surged 35.48% over the last five days and 72% over the past year, trading at $19.78 while remaining 20.88% below the 52-week high of $25.00.
The FDA BLA filing for z-rostudirsen on May 27, 2026, represents a critical regulatory milestone for the Duchenne muscular dystrophy treatment. Additionally, the company initiated a Phase III study on May 21, 2026, and is scheduled to present at the AMCP conference on April 14, 2026.
The stock faces significant headwinds with a short interest of 16.66% of the float and recent selling by a biotech fund of $14 million worth of shares. Furthermore, the sector has shown negative net buying flow over the last 90 days, with industry insiders selling 4.56% more than they bought.
Something here stands out, but not much.
| Filing → |
| ACGL | SELL | 2026-06-04 | $59K | — | Filing → |
| DYN | BUY | 2026-05-28 | $36K | — | Filing → |
| DYN | BUY | 2026-05-22 | $43K | — | Filing → |